Peter W. Heald, M.D.

Professor of Dermatology, Chief of Dermatology Service VA Medical Center

Research Interests

The role of T cell surface proteins in cutaneous T cell lymphoma (CTCL) and the treatment of the disease. Cytofluorographic studies of T cell mediated diseases and apoptosis. The interactions between lymphoma cells and normal immunocytes involved in the anti-tumor response against those lymphoma cells. We have been developing diagnostic tests for permitting the early diagnosis of cutaneous T-cell lymphoma. Clinical research projects involve the multi-factorial assessment of immunocompetence and tumor burden by way of antibody in molecular studies of patients' samples.

Education:	1975 B.A., Dartmouth 1978 MD, Duke
Training:	Fellowship: University of Pennsylvania

Selected Publications

• Suga Y, Duncan K, Heald P, Roop D. A novel helix termination mutation in keratin 10 in annular epidermolytic ichthyosis, a variant of bullous congenital ichthyosiform erythroderma. J Invest Dermatol 111:1220, 1998.
• Duncan KO, Heald PW. T-cell technology in the diagnosis and management of cutaneous T-celllymphoma. Comp Therapy 24: 117, 1998.
• Girardi M, McNiff J, Heald PW. Extracorporeal photochemotherapy in human and murine graft-versus-host disease. Dermatol Sci 19: 106-13, 1999.
• Vu A, Radonich M, Heald P. Herpes zoster in seven disparate dermatomes (zoster multiplex): Report of a case and review of the literature. J Am Acad Dermatol 40: 868-9, 1999.
• Heald P. Cutaneous T-cell lymphoma as the prototype for T-cell mediated cutaneous disease. Current Practice of Medicine 1:118, 1999.
• Heald P, Duncan KO. Weekly Clinicopathological Exercises: Case 12-1998: A 68-year old man with a rash, diabetes insipidus, and laryngeal stenosis. N Engl J Med 338: 1138, 1998.
• Duncan KO, Heald PW. Cutaneous T-cell lymphoma: Centuries of controversy. Sem Cutaneous Med Surg 17: 133, 1998.
• Sinha A, Heald PW. Advances in the management of cutaneous T-cell lymphoma. Dermatol Clin 16:301, 1998.
• Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, et al. Pivotal phase III trial of two dose levels of DAB-389 IL-2 for the treatment of cutaneous T-cell lymphoma. J Clin Oncol (in press).
• Schechner JS, Edelson RL, McNiff JM, Heald PW, Pober JS. Expression of Integrin a4b7 on epidermotropic cutaneous T cells in cutaneous T cell lymphoma and spongiotic dermatitis. Lab Invest 79:601-607, 1999.
• Heald P, Glusac EJ. Unilesional cutaneous T-cell lymphoma: clinical features, therapy and follow-up of ten patients with a treatment responsive mycosis fungoides variant. J Am Acad Dermatol (in press).
• Heald P, Yan SL, Latkowski J, Edelson R. Profound deficiency in normal circulating T-cells in erythrodermic cutaneous T-cell lymphoma. Arch Dermatol 130:198-203, 1994.
• Heald P, Laroche L, Knobler R. Photoinactivated lymphocyte therapy of cutaneous T-cell lymphoma. Dermatol Clinic 12(2):443-449, 1994.
• Wood GS, Tung RM, Crooks CF, Haeffner A, Liao S, Orozco BA, Vellken H, Kadin M, Koh H, Heald P, Barnhill RL, Sklar J. Detection of early cutaneous T cell lymphoma. J Invest Dermatol 103:34-41, 1994.
• Heald P. cutaneous T-cell lymphoma: therapy. In Cutaneous Medicine and Surgery. Arndt K et al (eds) 1994.
• Heald P, Edelson R: Malignant lymphocytes -classic disease description and pathophysiology. In Cutaneous Medicine and Surgery. Arndt K et al (eds) 1994.

Book Chapters

• Heald PW, Edelson RL. Cutanseous Lymphomas. In: Dermatology in General Medicine, Fitzpatrick TB et al (eds) 1998.
• Heald PW and Edelson RL. Cutaneous T-cell Lymphoma. In: Malignant Tumors of the Skin. Chu AC and Edelson RL, eds. Edward Arnold, 1999.

 

Contact

Campus Address
Yale School of Medicine
333 Cedar Street
New Haven, CT 06520-8059

Email
peter.heald@yale.edu

Office Phone
(203) 785-6370